Linked Life Data

19642320

Source:http://linkedlifedata.com/resource/pubmed/id/19642320

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-7-31
pubmed:abstractText
The colorectal cancer treatment has significantly changed in last few years. Use of new drugs such as oxaliplatin, irinotecan, or capecitabine improved long term survival of patient with this disease. Research of biologic and genetic behavior of CRC has brought new ways in therapy called "biologic therapy". Standard today's treatment consist of three drugs: bevacizumab (antiVEGF antibody), cetuximab and panitumimab (anti EGFR antibodies). Biology therapy should be used simultaneously with chemotherapy only and after genetic examination of the cancer (K ras mutation). For patients with stage III the adjuvant therapy with combination of FOLFOX (oxaliplatin, fluorouracil, and leukovorin) is recommended to reduce the probability of recurrence and improve survival. In stage IIB there is a clear need to determine further risks which classify the high risk patients who should be enrolled in adjuvant chemotherapy. In palliative treatment of colorectal cancer there are several chemotherapy combinations (FUFA, FOLFOX, FOLFIRI, XELOX, XELIRI) used with biologic therapy. International recommendation for the biologic therapy is in the first line treatment bevacizumab and cetuximab or panitumumab in the second line is recommended. The new discoveries in biology of colorectal cancer show the need of tailoring.
pubmed:language
cze
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0035-9351
pubmed:author
pubmed:issnType
Print
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-7
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Chemotherapy and biological treatment in the complex management of large intestinal and rectal carcinomas. When, why, how?].
pubmed:affiliation
Onkologická klinika VFN a UK 1. LF, Praha.
pubmed:publicationType
Journal Article, English Abstract, Review